000162298 001__ 162298
000162298 005__ 20251017144606.0
000162298 0247_ $$2doi$$a10.1038/s41598-025-09822-1
000162298 0248_ $$2sideral$$a144870
000162298 037__ $$aART-2025-144870
000162298 041__ $$aeng
000162298 100__ $$aPaesa, Mónica$$uUniversidad de Zaragoza
000162298 245__ $$aUnveiling the therapeutic potential of phenolic compounds from Boletus edulis in osteoarthritis treatment
000162298 260__ $$c2025
000162298 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162298 5203_ $$aOsteoarthritis (OA) is a joint disease characterized by inflammation, cartilage degeneration, and pain. Recent studies have focused on the potential of active phenolic compounds as a treatment for OA, owing to their anti-inflammatory, antioxidant, and chondroprotective effects. Specifically, Boletus edulis (BE) extracts, a natural product from mushrooms, have been shown as significantly active compounds against oxidative stress and inflammation. Our aim was to evaluate the anti-inflammatory and chondroprotective potential of BE extracts, primarily composed of phenolic compounds and flavonoids, in OA in vitro models. Our results showed that cell treatment with 250 µg/mL of BE extracts maintained cell viability above 70% without affecting apoptosis or cell cycle. At the molecular level, BE extracts exerted anti-inflammatory effects by reducing nitric oxide (NO) levels, as well as the expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines and chemokines (interleukin-6 (IL-6), IL-8, (C-X-C motif) ligand 1 (CXCL-1)) in lipopolysaccharide (LPS)-stimulated cells. Additionally, BE extracts treatment demonstrated a significant decrease in matrix metalloproteinases 3 and 13 (MMP-3, MMP-13) expression, while avoiding the depletion in the expression of chondrogenic markers, aggrecan and collagen II. Furthermore, inflammation was also significantly reduced through the inhibition of p65 nuclear translocation. These findings suggest that BE extracts may provide a promising basis for the development of novel therapeutic strategies in the treatment of OA, reducing inflammation and chondrocytes damage.
000162298 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B55$$9info:eu-repo/grantAgreement/ES/IISAragón/FSE-I-01/Intramural23$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI21-00911$$9info:eu-repo/grantAgreement/ES/ISCIII/FORT23-00028
000162298 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000162298 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162298 700__ $$aIzquierdo, Mauricio David
000162298 700__ $$aRemírez de Ganuza, Cristina$$uUniversidad de Zaragoza
000162298 700__ $$aFerreira-Santos, Pedro
000162298 700__ $$0(orcid)0000-0002-3595-7668$$aRodríguez-Yoldi, María Jesús$$uUniversidad de Zaragoza
000162298 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, Gracia
000162298 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000162298 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000162298 7102_ $$15005$$2790$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Tecnologi. Medio Ambiente
000162298 773__ $$g15, 1 (2025), 15 pp.$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322
000162298 8564_ $$s2435811$$uhttps://zaguan.unizar.es/record/162298/files/texto_completo.pdf$$yVersión publicada
000162298 8564_ $$s2525887$$uhttps://zaguan.unizar.es/record/162298/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162298 909CO $$ooai:zaguan.unizar.es:162298$$particulos$$pdriver
000162298 951__ $$a2025-10-17-14:15:41
000162298 980__ $$aARTICLE